title: Evaluation of anticonvulsant effect of two novels 4-[1-(4-fluorobenzyl)- 5-imidazolyl] dihydropyridine derivatives in mice.
abstract: In this study the anticonvulsant effect of two dihydropyridine derivatives [diethyl -1,4- dihydro -2,6-dimethyl -4-(4- fluoro benzyl-2- methylthio -5- imidazolyl)-3,5- pyridine dicarboxilat (A) and diethyl -1,4-dihydro -2,6- diethyl -4-(4- fluoro benzyl-2- methylthio -5- imidazolyl)-3,5- pyridine dicarboxilat (B)] by pentylenetetrazole (PTZ) and electroshock in mice was evaluated. The latency and HLTE (hind limb tonic extensions), the duration of HLTE and the mortality protection in pentylenetetrazole test and the HLTE duration in electroshock test were assessed. Both compounds had significant differences with negative control in all doses used. There was no significant difference between nifedipine and B (96.7 and 169.2 mg/kg doses) in the starting point of HLTE and between nifedipine andA(62.2 and 108.9 mg/kg doses) in the duration of HLTE in the PTZ test. Also, there was no significant difference between nifedipine and B (96.7 and 169.2 mg/kg doses) andA(62.2 and 108.9 mg/kg doses) in electroshock test. All doses ofAand B and nifedipine showed less effect than phenytoin and valproate. This study showed that bothAand B have anticonvulsant activity in the PTZ-induced seizure model and the MES test. These compounds, thus, might be useful in the petit mal and grand mal epilepsy.
authors.affiliation: Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.
authors.forename: F
authors.initials: F
authors.lastname: Hadizadeh
authors.forename: B
authors.initials: B
authors.lastname: Rahimi
authors.forename: E
authors.initials: E
authors.lastname: Taghiabadi
authors.forename: M
authors.initials: M
authors.lastname: Razavi
authors.forename: G
authors.initials: G
authors.lastname: Karimi
keywords: Anticonvulsant; Calcium; Dihydropyridine; Electroshock; Pentylenetetrazole; Seizure; channel blocker
references.citation: Neurosci Lett. 2007 Feb 14;413(2):168-72
references.pmid: 17240061
references.citation: J Hypertens. 2010 Jun;28(6):1321-9
references.pmid: 20224431
references.citation: J Ethnopharmacol. 2004 Mar;91(1):167-70
references.pmid: 15036484
references.citation: Phytomedicine. 2007 Apr;14(4):256-62
references.pmid: 16707256
references.citation: Lancet. 1986 Jun 7;1(8493):1303-4
references.pmid: 2872433
references.citation: Eur J Pharmacol. 2006 Oct 10;547(1-3):65-74
references.pmid: 16930590
references.citation: Bioorg Med Chem Lett. 2011 Mar 15;21(6):1692-6
references.pmid: 21316226
references.citation: Pharmacol Ther. 2010 Nov;128(2):274-80
references.pmid: 20705092
references.citation: Brain Res. 1998 Jun 15;796(1-2):311-4
references.pmid: 9689485
references.citation: Neuropharmacology. 2010 May;58(6):855-64
references.pmid: 20146928
references.citation: Epilepsia. 1995;36 Suppl 1:S23-9
references.pmid: 23057107
references.citation: Farmaco. 2004 Apr;59(4):261-9
references.pmid: 15081343
references.citation: Br Med J (Clin Res Ed). 1986 May 3;292(6529):1170-1
references.pmid: 3085769
references.citation: Epilepsy Res. 2003 Jan;52(3):215-25
references.pmid: 12536054
references.citation: Gen Pharmacol. 1992 Nov;23(6):1205-16
references.pmid: 1283140
references.citation: Clin Exp Hypertens. 2012;34(3):191-200
references.pmid: 21967023
references.citation: Toxicol Lett. 2002 Mar 24;129(1-2):123-32
references.pmid: 11879983
references.citation: Clin Exp Hypertens. 2011;33(4):231-9
references.pmid: 21699449
references.citation: Lancet. 1986 Mar 29;1(8483):700-3
references.pmid: 2870222
references.citation: Bioorg Med Chem Lett. 2010 Sep 1;20(17):5147-52
references.pmid: 20673719